Pathologists Vary in Suggested Therapy for Melanocytic Lesions

Share this content:
Pathologists Vary in Suggested Therapy for Melanocytic Lesions
Pathologists Vary in Suggested Therapy for Melanocytic Lesions

TUESDAY, Dec. 20, 2016 (HealthDay News) -- Pathologists have wide variability in treatment suggestions for melanocytic lesions, according to a study published in the January issue of the Journal of the American Academy of Dermatology.

Kachiu C. Lee, M.D., from Brown University in Providence, R.I., and colleagues conducted a survey to assess variability in 207 pathologists' treatment suggestions for melanocytic lesions in their reports.

The researchers found that 15 percent of pathologists reported never including suggestions and 7 percent reported always including suggestions. Improved care (79 percent), clarification (68 percent), and legal liability (39 percent) were cited as reasons for offering suggestions, while referring physician preference (48 percent), lack of clinical information (44 percent), and expertise (29 percent) were cited reasons for not offering suggestions. Offering suggestions were associated with training and caseload (P < 0.05). Suggestions were most consistent for mild/moderate dysplastic nevi and melanoma. For melanoma in situ, 9 percent of pathologists made treatment suggestions that undertreated legions and 15 percent made suggestions overtreating lesions, based on National Comprehensive Cancer Network (NCCN) guidelines. Seven percent of pathologists made treatment suggestions that undertreated lesions for invasive melanoma, based on NCCN guidelines.

"These findings may inform efforts to reduce treatment variability and optimize patterns of care delivery for patients," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Keytruda for All Cancers With Genetic Biomarker

FDA Approves Keytruda for All Cancers With Genetic ...

First medication sanctioned for any cancer, regardless of origin

Regular Chocolate Consumption May Lower Risk of A-Fib

Regular Chocolate Consumption May Lower Risk of A-Fib

13-year study finds lower odds for atrial fibrillation in people eating moderate amounts

Doctors Urged to Check Patient Drug History Before Opioid Rx

Doctors Urged to Check Patient Drug History Before ...

Opioid abuse down when physicians are legally obligated to check patient's drug history

is free, fast, and customized just for you!

Already a member?

Sign In Now »